1-4 of 4
Fang-Shu Ou, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Carla Casulo, MD, Jennifer Le-Rademacher, PhD, Jesse Dixon, Stat, Gilles Salles, MD, Eva Hoster, Michael Herold, MD, Wolfgang Hiddemann, Catherine Sebban, MD, Robert Marcus, Eva Kimby, Howard Hochster, MD, Umberto Vitolo, MD, Emmanuel Gyan, MDPhD, Fang-Shu Ou, PhD, Tina Nielsen, Kenneth A. Foon, MD, Shi Qiuan, PhD, Christopher Flowers, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 412.
https://doi.org/10.1182/blood.V130.Suppl_1.412.412
Published: 2017
Journal Articles

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Christopher Flowers, MDMS, Fang-Shu Ou, PhD, Qian Shi, PhD, Eva Hoster, PhD, Bruce A. Peterson, MD, Howard S. Hochster, MD, Pauline Brice, MD, Marco Ladetto, MD, Wolfgang Hiddemann, MD, Robert E Marcus, Eva Kimby, MD PhD, Michael Herold, Sabine De Bedout, MD MPH, Tina Nielsen, Franck Morschhauser, Mathias Rummel, MD PhD, Anton Hagenbeek, MD PhD, Umberto Vitolo, Gilles A. Salles, Daniel Sargent, PhD
Journal: Blood
Blood (2016) 128 (22): 1102.
https://doi.org/10.1182/blood.V128.22.1102.1102
Published: 2016
Journal Articles

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Qian Shi, PhD, Norbert Schmitz, MD, PhD, Christopher Flowers, MD MS, Fang-Shu Ou, PhD, David Cunningham, Michael Pfreundschuh, MD, John F Seymour, Ulrich Jaeger, Thomas M. Habermann, MD, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Herve Ghesquieres, MD PhD, Francesco Merli, Marita Ziepert, Raoul Herbrecht, MD, Jocelyne Flament, MD, Tommy Fu, PhD, Bertrand Coiffier, MD PhD, Daniel Sargent, PhD
Journal: Blood
Blood (2016) 128 (22): 4196.
https://doi.org/10.1182/blood.V128.22.4196.4196
Published: 2016
Journal Articles

Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients

Matthew J Maurer, MS, Thomas M. Habermann, MD, Qian Shi, PhD, Norbert Schmitz, MD, PhD, David Cunningham, Michael Pfreundschuh, MD, PhD, John F. Seymour, MD, Ulrich Jaeger, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Herve Ghesquieres, MD PhD, Francesco Merli, Marita Ziepert, Raoul Herbrecht, MD, Jocelyne Flament, MD, Tommy Fu, PhD, Christopher Flowers, MDMS, Fang-Shu Ou, PhD, Daniel Sargent, PhD, Bertrand Coiffier, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3027.
https://doi.org/10.1182/blood.V128.22.3027.3027
Published: 2016